Baillie Gifford & Co. Lowers Position in BioNTech SE Sponsored ADR $BNTX

Baillie Gifford & Co. decreased its holdings in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 2.0% during the third quarter, according to its most recent filing with the SEC. The firm owned 7,879,359 shares of the company’s stock after selling 159,513 shares during the period. Baillie Gifford & Co. owned 3.50% of BioNTech worth $777,062,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BNTX. BNP Paribas Financial Markets boosted its stake in shares of BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock valued at $135,800,000 after purchasing an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp boosted its position in BioNTech by 58.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after acquiring an additional 410,351 shares in the last quarter. Dodge & Cox purchased a new position in shares of BioNTech in the 2nd quarter valued at $93,421,000. Franklin Resources Inc. increased its holdings in shares of BioNTech by 76.8% in the 2nd quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock valued at $80,065,000 after acquiring an additional 326,556 shares during the period. Finally, Aberdeen Group plc raised its position in shares of BioNTech by 87.2% in the 2nd quarter. Aberdeen Group plc now owns 721,928 shares of the company’s stock worth $76,864,000 after acquiring an additional 336,260 shares in the last quarter. Institutional investors own 15.52% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $121.00 to $120.00 and set a “neutral” rating on the stock in a report on Thursday, October 23rd. UBS Group raised shares of BioNTech to a “hold” rating in a research report on Thursday, December 4th. Berenberg Bank reissued a “buy” rating on shares of BioNTech in a research report on Friday. Finally, TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. Eleven investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $140.03.

BioNTech Stock Down 2.1%

NASDAQ:BNTX opened at $115.98 on Friday. The company has a current ratio of 7.12, a quick ratio of 7.02 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a twelve month low of $81.20 and a twelve month high of $126.77. The company has a market cap of $26.12 billion, a PE ratio of -44.10 and a beta of 1.40. The company’s 50 day moving average is $99.39 and its two-hundred day moving average is $103.74.

BioNTech (NASDAQ:BNTX) last posted its quarterly earnings data on Monday, November 3rd. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of $0.75 by ($0.89). BioNTech had a negative return on equity of 3.03% and a negative net margin of 17.91%.The company had revenue of $1.78 billion for the quarter, compared to analyst estimates of $1.21 billion. During the same quarter in the previous year, the firm posted $0.81 earnings per share. The company’s quarterly revenue was up 22.0% on a year-over-year basis. Analysts anticipate that BioNTech SE Sponsored ADR will post -3.88 EPS for the current year.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.